Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934655 · ClinicalTrials.gov registry record · Phase 3
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
A Phase 3 study, sponsored by Children's Hospital Los Angeles.
- Not yet
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT06934655: Clinical Trial Phase 3 study, sponsored by Children's Hospital Los Angeles.
NCT06934655 is a Phase 3 study that has not yet begun recruiting, run by Children's Hospital Los Angeles. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06934655, a Phase 3 study, has not yet begun recruiting, sponsored by Children's Hospital Los Angeles.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.
Primary Outcome
Percent Body Mass Index (%BMI) is calculated as the participant's BMI at each assessment time point expressed as a percentage of the 95th percentile BMI for age and sex, based on CDC growth charts. This metric is commonly used in pediatric populations to more accurately reflect degrees of obesity in youth, particularly at the upper end of the BMI distribution where standard BMI z-scores may lose sensitivity. Calculation Formula: %BMI = (Participant's BMI / 95th percentile BMI for age and sex)
Interventions
- DRUG Semaglutide 2.4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2033-11-01 |
| Phase | Phase 3 |
What is known before NCT06934655 opens enrollment
NCT06934655 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Semaglutide 2.4 mg is the first listed.
NCT06934655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06934655 about?
NCT06934655 is a clinical study titled "Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth". This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutid...
What is the current status of trial NCT06934655?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-06-01. Estimated completion is 2033-11-01.
What interventions are being tested in trial NCT06934655?
The interventions under investigation include: Semaglutide 2.4 mg (DRUG).
Who is sponsoring clinical trial NCT06934655?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06934655's enrollment target sits among peer trials
150 1519th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI